Conferences - Results from #80

Viewing 81-100 of 11872 articles

SUO 2024: E-cigarette Use and the Risk of Bladder Cancer

SUO 2024: Implementing Smoking Cessation in the Urologic Oncology Setting

SUO 2024: Characteristics, Treatment Patterns, and Outcomes of African American Versus Caucasian Patients with Metastatic Castration-Resistant Prostate Cancer: Post Hoc Analysis of TRUMPET Registry

SUO 2024: Comparative Analysis of PSMA-PET Imaging in Detecting Radio-Recurrent Prostate Cancer Above and Below Phoenix Criteria Thresholds

SUO 2024: A Phase III Study of 177Lu-TLX591 plus Standard-of-Care Versus Standard-of-Care Alone in Patients with mCRPC (PROSTACT GLOBAL)

SUO 2024: Mevrometostat (PF-06821497) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate: The Phase III Randomized Enz Study

SUO 2024: Management of the Bladder in Metastatic Patients Following Complete Response to Systemic Therapy: Is There a Role for Consolidative Local Therapy?

SUO 2024: Adjuvant Radiation Following Cystectomy: Underutilized Therapy?

SUO 2024: The Evolution of First-Line Treatment for Metastatic Urothelial Cancer

SUO 2024: Precision in Urothelial Carcinoma: Overarching Theme 2 – ctDNA-Based Clinical Decision-Making in Urothelial Cancer: What Do We Know in 2024?

SUO 2024: A Personalized and Pragmatic Approach to (P)rehabilitation for Patients with Bladder Cancer

SUO 2024: Emerging Treatments and New Targets for Metastatic Urothelial Cancer

SUO 2024: New Approaches to NMIBC Surgery

SUO 2024: Keynote Lecture: Precision in Urothelial Carcinoma – FGFR

SUO 2024: Emerging Perioperative Systemic Therapy

SUO 2024: Heterogeneity of Intermediate Risk NMIBC

SUO 2024: BCG Unresponsive Cancer in 2024

SCS AUA 2024: Pelvic Exenteration and Urologic Complications: A 90-Day Audit of the Practice at a Single Tertiary Level Medical Center

SCS AUA 2024: Multiparametric MRI in the Evaluation of Small Renal Masses

SCS AUA 2024: Financial Toxicity in Testicular Cancer Treatment, Validated Questionnaire Correlated Software Cost Modeling

1
2
3
4
5
6
7
8
9
10